Literature DB >> 19627189

Mucosal vaccines: novel advances in technology and delivery.

Yoshikazu Yuki1, Hiroshi Kiyono.   

Abstract

Mucosal vaccines are considered the most suitable type of vaccines to combat emerging and re-emerging infectious diseases because of their ability to induce both mucosal and systemic immunity. Considerable advances have been made toward the development of mucosal vaccines against influenza virus and rotavirus. Many additional mucosal vaccines are in development, including vaccines against cholera, typhoid, traveler's diarrhea and respiratory infections. In addition to oral and nasal vaccines, transcutaneous (or skin patch) and sublingual immunizations are now part of a new generation of mucosal vaccines. Furthermore, a rice-based oral vaccine (MucoRice) has been receiving global attention as a new form of cold chain-free vaccine, because it is stable at room temperature for a prolonged period. This review describes recent developments in mucosal vaccines with promising preclinical and clinical results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19627189     DOI: 10.1586/erv.09.61

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  29 in total

1.  Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.

Authors:  Aziz Alami Chentoufi; Gargi Dasgupta; Anthony B Nesburn; Ilham Bettahi; Nicholas R Binder; Zareen S Choudhury; Winston D Chamberlain; Steven L Wechsler; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

2.  Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus.

Authors:  Pei-Feng Liu; Yanhan Wang; Yu-Tsueng Liu; Chun-Ming Huang
Journal:  J Nat Sci       Date:  2017-02

Review 3.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

4.  Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Authors:  Lissette S Velasquez; Samantha Shira; Alice N Berta; Jacquelyn Kilbourne; Babu M Medi; Ian Tizard; Yawei Ni; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Vaccine       Date:  2011-06-02       Impact factor: 3.641

Review 5.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

Review 6.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

Review 7.  Mucosal Lactobacillus vectored vaccines.

Authors:  Qinghua Yu; Liqi Zhu; Haihong Kang; Qian Yang
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

Review 8.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

9.  Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.

Authors:  Byoung-Shik Shim; Jung-Ah Choi; Ho-Hyun Song; Sung-Moo Park; In Su Cheon; Ji-Eun Jang; Sun Je Woo; Chung Hwan Cho; Min-Suk Song; Hyemi Kim; Kyung Joo Song; Jae Myun Lee; Suhng Wook Kim; Dae Sub Song; Young Ki Choi; Jae-Ouk Kim; Huan Huu Nguyen; Dong Wook Kim; Young Yil Bahk; Cheol-Heui Yun; Man Ki Song
Journal:  J Microbiol       Date:  2013-03-02       Impact factor: 3.422

Review 10.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.